FDA panel backs Astellas Pharma's new antifungal treatment

January 24, 2015 1:58 PM

2 0

An advisory panel to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend isavuconazonium (ISA) (Cresemba, Astellas Pharma, Inc.) for the treatment of adults with invasive aspergillosis (IA).

In recent clinical trials, this drug proved to be effective and safe in the reduction of mortality when compared against voriconazole, a drug sold by Pfizer under the label Vfend, to treat aspergillosis. In reality, the Pfizer drug is the current industry standard for treatment of this condition.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page